Policy | September 14, 2022
Mandaviya launches NLEM 2022
This will give a boost to cost-effective, quality medicines and contribute towards reduction in out of pocket expenditure on healthcare for the citizens
This will give a boost to cost-effective, quality medicines and contribute towards reduction in out of pocket expenditure on healthcare for the citizens
At present 18 per cent of the local pharmaceutical market is under government's price control
Stable profits, low leverage to keep credit profiles comfortable
The company is committed to a new category development in areas like adult Immunization with products like Shingrix to make a positive impact to the lives of the patients in India
The current ruling will assure the safety of the use of Ranitidine for Indian patients
ICRA expects the OPM of the sample set to moderate to 20.2% in FY2023 from 21.5% in FY2022.
Acute therapies continue to report strong growth compared to chronic ones.
A total of 526 brands has seen a reduction of up to 90 per cent in MRP
The government has taken all the effective measures to make healthcare affordable
The company continued to maintain clear FDA status across its plants and has received 12 ANDA approvals during 9MFY21
Subscribe To Our Newsletter & Stay Updated
